CDNA Quote, Financials, Valuation and Earnings

Co-Diagnostics, Inc. has a net margin of 1.67% compared to CareDx, Inc.'s net margin of -4048.69%. CareDx, Inc.'s return on equity of 21.1% beat Co-Diagnostics, Inc.'s return on equity of -65.15%.

CareDx, Inc. has a consensus price target of $22.00, signalling upside risk potential of 7.06%. On the other hand Co-Diagnostics, Inc. has an analysts' consensus of $1.50 which suggests that it could grow by 1792.03%. Given that Co-Diagnostics, Inc. has higher upside potential than CareDx, Inc., analysts believe Co-Diagnostics, Inc. is more attractive than CareDx, Inc..

CareDx, Inc. has a beta of 2.490, which suggesting that the stock is 148.978% more volatile than S&P 500. In comparison Co-Diagnostics, Inc. has a beta of 1.248, suggesting its more volatile than the S&P 500 by 24.773%.

CareDx, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Co-Diagnostics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CareDx, Inc. pays -- of its earnings as a dividend. Co-Diagnostics, Inc. pays out -- of its earnings as a dividend.

CareDx, Inc. quarterly revenues are $100.1M, which are larger than Co-Diagnostics, Inc. quarterly revenues of $145.4K. CareDx, Inc.'s net income of $1.7M is higher than Co-Diagnostics, Inc.'s net income of -$5.9M. Notably, CareDx, Inc.'s price-to-earnings ratio is 17.23x while Co-Diagnostics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CareDx, Inc. is 3.18x versus 41.58x for Co-Diagnostics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Electromed, Inc. has a net margin of 1.67% compared to CareDx, Inc.'s net margin of 12.65%. CareDx, Inc.'s return on equity of 21.1% beat Electromed, Inc.'s return on equity of 18.89%.

CareDx, Inc. has a consensus price target of $22.00, signalling upside risk potential of 7.06%. On the other hand Electromed, Inc. has an analysts' consensus of $36.00 which suggests that it could grow by 20.52%. Given that Electromed, Inc. has higher upside potential than CareDx, Inc., analysts believe Electromed, Inc. is more attractive than CareDx, Inc..

CareDx, Inc. has a beta of 2.490, which suggesting that the stock is 148.978% more volatile than S&P 500. In comparison Electromed, Inc. has a beta of 0.266, suggesting its less volatile than the S&P 500 by 73.442%.

CareDx, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CareDx, Inc. pays -- of its earnings as a dividend. Electromed, Inc. pays out -- of its earnings as a dividend.

CareDx, Inc. quarterly revenues are $100.1M, which are larger than Electromed, Inc. quarterly revenues of $16.9M. CareDx, Inc.'s net income of $1.7M is lower than Electromed, Inc.'s net income of $2.1M. Notably, CareDx, Inc.'s price-to-earnings ratio is 17.23x while Electromed, Inc.'s PE ratio is 32.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CareDx, Inc. is 3.18x versus 3.98x for Electromed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

InfuSystem Holdings, Inc. has a net margin of 1.67% compared to CareDx, Inc.'s net margin of 6.19%. CareDx, Inc.'s return on equity of 21.1% beat InfuSystem Holdings, Inc.'s return on equity of 9.93%.

CareDx, Inc. has a consensus price target of $22.00, signalling upside risk potential of 7.06%. On the other hand InfuSystem Holdings, Inc. has an analysts' consensus of $14.20 which suggests that it could grow by 71.91%. Given that InfuSystem Holdings, Inc. has higher upside potential than CareDx, Inc., analysts believe InfuSystem Holdings, Inc. is more attractive than CareDx, Inc..

CareDx, Inc. has a beta of 2.490, which suggesting that the stock is 148.978% more volatile than S&P 500. In comparison InfuSystem Holdings, Inc. has a beta of 1.680, suggesting its more volatile than the S&P 500 by 68.01%.

CareDx, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. InfuSystem Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CareDx, Inc. pays -- of its earnings as a dividend. InfuSystem Holdings, Inc. pays out -- of its earnings as a dividend.

CareDx, Inc. quarterly revenues are $100.1M, which are larger than InfuSystem Holdings, Inc. quarterly revenues of $36.5M. CareDx, Inc.'s net income of $1.7M is lower than InfuSystem Holdings, Inc.'s net income of $2.3M. Notably, CareDx, Inc.'s price-to-earnings ratio is 17.23x while InfuSystem Holdings, Inc.'s PE ratio is 31.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CareDx, Inc. is 3.18x versus 1.24x for InfuSystem Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings, Inc. has a net margin of 1.67% compared to CareDx, Inc.'s net margin of 3.93%. CareDx, Inc.'s return on equity of 21.1% beat Xtant Medical Holdings, Inc.'s return on equity of 3.78%.

CareDx, Inc. has a consensus price target of $22.00, signalling upside risk potential of 7.06%. On the other hand Xtant Medical Holdings, Inc. has an analysts' consensus of $1.50 which suggests that it could grow by 145.9%. Given that Xtant Medical Holdings, Inc. has higher upside potential than CareDx, Inc., analysts believe Xtant Medical Holdings, Inc. is more attractive than CareDx, Inc..

CareDx, Inc. has a beta of 2.490, which suggesting that the stock is 148.978% more volatile than S&P 500. In comparison Xtant Medical Holdings, Inc. has a beta of -0.077, suggesting its less volatile than the S&P 500 by 107.701%.

CareDx, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CareDx, Inc. pays -- of its earnings as a dividend. Xtant Medical Holdings, Inc. pays out -- of its earnings as a dividend.

CareDx, Inc. quarterly revenues are $100.1M, which are larger than Xtant Medical Holdings, Inc. quarterly revenues of $33.3M. CareDx, Inc.'s net income of $1.7M is higher than Xtant Medical Holdings, Inc.'s net income of $1.3M. Notably, CareDx, Inc.'s price-to-earnings ratio is 17.23x while Xtant Medical Holdings, Inc.'s PE ratio is 59.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CareDx, Inc. is 3.18x versus 0.67x for Xtant Medical Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.